Search research articles
Contact Us
Filters
Showing results (471-480 of 713) with videos related to
Page
of 72
Sort By:
Blood
|
April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
American Journal of Hematology
|
May 29, 2015
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D DiNardo, Farhad Ravandi, Sam Agresta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
Yiming Chen, Jorge Cortes, Zeev Estrov, et al.
Blood
|
December 16, 2010
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
Elias Jabbour, Jorge Cortes, Fabio P S Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
Jorge Cortes, Stefan Faderl, Elihu Estey, et al.
The Lancet. Haematology
|
December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Cancer Genetics
|
September 19, 2015
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation
Maro Ohanian, Carlos Bueso-Ramos, Chi Young Ok, et al.
Scientific Reports
|
August 19, 2022
Understanding geographic and racial/ethnic disparities in mortality from four major cancers in the state of Georgia: a spatial epidemiologic analysis, 1999-2019
Justin Xavier Moore, Martha S Tingen, Steven S Coughlin, et al.
Cancer
|
April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
Ruben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Cancer
|
August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
Maher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Page
of 72
Search research articles
Search
Showing results (471-480 of 713) with videos related to
Sort By:
Page
of 72
Blood
|
April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
American Journal of Hematology
|
May 29, 2015
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D DiNardo, Farhad Ravandi, Sam Agresta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
Yiming Chen, Jorge Cortes, Zeev Estrov, et al.
Blood
|
December 16, 2010
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
Elias Jabbour, Jorge Cortes, Fabio P S Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2005
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
Jorge Cortes, Stefan Faderl, Elihu Estey, et al.
The Lancet. Haematology
|
December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Cancer Genetics
|
September 19, 2015
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation
Maro Ohanian, Carlos Bueso-Ramos, Chi Young Ok, et al.
Scientific Reports
|
August 19, 2022
Understanding geographic and racial/ethnic disparities in mortality from four major cancers in the state of Georgia: a spatial epidemiologic analysis, 1999-2019
Justin Xavier Moore, Martha S Tingen, Steven S Coughlin, et al.
Cancer
|
April 12, 2011
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
Ruben A Mesa, Hagop Kantarjian, Ayalew Tefferi, et al.
Cancer
|
August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
Maher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Page
of 72